Return-Path: jm@dogma.slashnull.org
Delivery-Date: Tue, 20 Mar 2001 23:22:07 +0000
Return-Path:
Delivered-To: jm@netnoteinc.com
Received: from dogma.slashnull.org (dogma.slashnull.org [212.17.35.15])
by mail.netnoteinc.com (Postfix) with ESMTP id 48C691140B7
for ; Tue, 20 Mar 2001 23:22:04 +0000 (GMT)
Received: (from jm@localhost)
by dogma.slashnull.org (8.9.3/8.9.3) id XAA30910
for jm@netnoteinc.com; Tue, 20 Mar 2001 23:22:03 GMT
Received: from eros.cs.jhu.edu (eros.cs.jhu.edu [128.220.223.245])
by dogma.slashnull.org (8.9.3/8.9.3) with ESMTP id XAA30905
for ; Tue, 20 Mar 2001 23:22:02 GMT
Received: from eros.cs.jhu.edu (IDENT:mailman@localhost.localdomain [127.0.0.1])
by eros.cs.jhu.edu (8.11.0/8.11.0) with ESMTP id f2KNM5Q23320;
Tue, 20 Mar 2001 18:22:06 -0500
Received: from mail.eros-os.org (IDENT:root@EROS.CIS.UPENN.EDU [158.130.6.119])
by eros.cs.jhu.edu (8.11.0/8.11.0) with ESMTP id f2KNLWQ23308
for ; Tue, 20 Mar 2001 18:21:32 -0500
Received: from exchange.technologynet.com (216-203-196-100.customer.algx.net [216.203.196.100])
by mail.eros-os.org (8.9.3/8.9.3) with SMTP id TAA00813
for ; Tue, 20 Mar 2001 19:07:40 -0500
Received: from SMTP agent by mail gateway
Tue, 20 Mar 2001 18:20:41 -0800
Received: from prodigy.com (DNS1 [10.1.1.1]) by exchange.technologynet.com with SMTP (Microsoft Exchange Internet Mail Service Version 5.5.2653.13)
id HJ8D6AM4; Tue, 20 Mar 2001 18:21:28 -0500
Received: from SMTP agent by mail gateway
Tue, 20 Mar 2001 18:20:17 -0800
From:
To: dcms-dev@eros-os.org
Date: Tue, 20 Mar 2001 17:46:10
Message-Id: <141.825596.282112@msn.com>
Reply-To: biotechinfo2006@yahoo.com
Mime-Version: 1.0
Content-type: text/plain
Subject: [DCMS-Dev] FREE Biotech Stock Info! 721
Sender: dcms-dev-admin@mail.eros-os.org
Errors-To: dcms-dev-admin@mail.eros-os.org
X-BeenThere: dcms-dev@mail.eros-os.org
X-Mailman-Version: 2.0beta5
Precedence: bulk
List-Id: Discussion of the DCMS configuration management system
Do you want to capitalize on the Biotech Revolution
Do
you want to capitalize on the Biotech Revolution? Would you like to add
groundbreaking biotech, pharmaceutical and medical device companies to your
portfolio mix? Does hearing about exciting IPO and private placement offerings
from life sciences companies interest you?
The
exclusive Ruddy-Carlisle Biotech Infoline service keeps you abreast of
investment opportunities in the life sciences space. Just sign up for it once
and get important information instantly delivered to study at your leisure. Our
service is 100% FREE! Sign
up!
Ruddy-Carlisle
Biotech Infoline:
- Instantly
delivers key life sciences investment information directly to you!
- Learn
about biotech, pharmaceutical & medical device investment opportunities
before others!
- Includes
IPO & private placement information!
- 100%
FREE!
For
the entire last decade there were only three profitable biotech companies. At
the end of this year, ten are projected. At the end of 2003, over forty
are projected! The genomic promise is about to be delivered and investors know
it. The Ruddy-Carlisle Biotech Infoline provides you with critical,
decision-making, information that aids the chance of investment success in this
lucrative space. Sign
up!
Please
Note- Your information will only be
shared with companies that are in the life sciences space and pass our
rigorous inspection. Only the best opportunities will come to you.
Ruddy-Carlisle respects your privacy. Sign
up!
List Removal Instructions- Simply click here: remove
to be instantly and permanently removed from our list. Send the blank email to
the address specified. Please do not try to reply to this message.
_______________________________________________
dcms-dev mailing list
dcms-dev@mail.eros-os.org
http://www.eros-os.org/mailman/listinfo/dcms-dev